- Leukemia
- Liver Cancer
- Lung Cancer
- Lung Cancer – Non-Small Cell
- Lung Cancer – Small Cell
- Lymphoma
- Melanoma
- Mesothelioma
- Miscellaneous
- Multiple Myeloma
- Myelodysplastic Syndrome
- Neuroblastoma
- Non-Hodgkin’s Lymphoma
- Aggressive/Intermediate Grade Non-Hodgkin’s Lymphoma
- Follicular Lymphoma
- Highly Aggressive/High Grade Non-Hodgkin’s Lymphoma
- Indolent/Low Grade Non-Hodgkin’s Lymphoma
- Mantle Cell Non-Hodgkin’s Lymphoma
- Recurrent Non-Hodgkin’s Lymphoma
- Screening/Prevention Non-Hodgkin’s Lymphoma
- T-Cell Non-Hodgkin’s Lymphoma
- Osteosarcoma
- Ovarian Cancer
- Pancreatic Cancer
- Prostate Cancer
- Rectal Cancer
- Renal Cancer
- Retinoblastoma
- Sarcoma
- Skin Cancer
- Supportive Care
- Management and Prevention of Anemia Supportive Care
- Management and Prevention of Anorexia and Weight Loss Supportive Care
- Management and Prevention of Bone Complications Supportive Care
- Management and Prevention of Fatigue Supportive Care
- Management and Prevention of Mucositis Supportive Care
- Management and Prevention of Nausea and Vomiting Supportive Care
- Management and Prevention of Neutropenia Supportive Care
- Management and Prevention of Thrombocytopenia Supportive Care
- Testicular Cancer
- Throat Cancer
- Thyroid Cancer
- Uterine Cancer
- Vaginal Cancer
Cancer News
FDA Places Hold on a Trial Evaluating Genetically Engineered Immune Cells for Cancer Treatment
(07/18/2016)
The United States Food and Drug Administration (FDA) has placed a hold on a clinical trial, referred to as the ROCKET trial, due to side effects of the treatment that may be associated with 3 patient deaths. Chimeric antigen receptor (CAR) technology is an emerging treatment technique that has demonstrated significant effectiveness in the treatment … Continue reading "FDA Places Hold on a Trial Evaluating Genetically Engineered Immune Cells for Cancer Treatment"